Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2022 / May / Learning to ADAPT
Microbiology & Immunology Digital and computational pathology Infectious Disease Microbiology and Immunology Digital Pathology

Learning to ADAPT

New machine learning tool designs sensitive viral diagnostics

By Liv Gaskill 05/20/2022 News 2 min read

Share

Over the past two years, the COVID-19 pandemic has highlighted the importance of effective diagnostics for infectious diseases – not to mention the vital role testing has played in curbing the spread of SARS-CoV-2. Now, researchers have developed a fully automated system to predict the effectiveness of viral diagnostics and design optimal tests (1). Using CRISPR-based diagnostics, the team screened 19,209 diagnostic-target pairs and trained a deep neural network to predict the diagnosis. They then used combinatorial optimization to improve the model’s sensitivity to viral genomic variation – arriving at the Activity-informed Design with All-inclusive Patrolling of Targets (ADAPT) system.

“ADAPT is really about developing countermeasures that target the virus that’s circulating right now and being prepared to move with the virus as it changes,” said Pardis Sabeti, senior author of the study (2). “As we’ve watched SARS-CoV-2 adapt in real time, we’ve learned just how much we need to change with it and other viruses.”

The team used ADAPT to design diagnostics for 1,933 vertebrate-infecting viral species, detecting most species within two hours and all but three within 24 hours. Though the ADAPT deep neural network was trained for CRISPR-based diagnostics, the team highlights that it can also be applied to models for other sequence-based tests, such as qPCR. “At the core of building good diagnostics is knowing what to target and how to target it,” Sabeti said (2). “We spend a lot of time building technologies to do that, but we've shown that, with thoughtful algorithmic work, we can get these methods to work much, much better.”

As COVID-19 shifts towards endemicity, there will no doubt be a shift in the number and type of tests required in healthcare and community settings – with a focus on identifying a wider variety of circulating respiratory viruses as they evolve. Recognizing this, ADAPT predicts which guide RNAs will yield strong signals in tests applied to different viral strains and variants, meaning that it would be able to detect different lineages throughout a virus’ evolution. The researchers also built ADAPT using the latest viral genomes from public databases – and the system is fully automated, allowing it to stay up to date as new variants emerge.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. HC Metsky et al., Nat Biotechnol, [Online ahead of print] (2022). PMID: 35241837.
  2. Allessandra DiCorato (2022). Available at: https://bit.ly/3wiuDXW.

About the Author(s)

Liv Gaskill

During my undergraduate degree in psychology and Master’s in neuroimaging for clinical and cognitive neuroscience, I realized the tasks my classmates found tedious – writing essays, editing, proofreading – were the ones that gave me the greatest satisfaction. I quickly gathered that rambling on about science in the bar wasn’t exactly riveting for my non-scientist friends, so my thoughts turned to a career in science writing. At Texere, I get to craft science into stories, interact with international experts, and engage with readers who love science just as much as I do.

More Articles by Liv Gaskill

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Global Referral
Digital and computational pathology
Global Referral

January 12, 2024

10 min read

How digital pathology is transforming the delivery of remote second opinions

Cracking Colon Cancer
Digital and computational pathology
Cracking Colon Cancer

January 25, 2024

1 min read

How a new clinically approved AI-based tool enables rapid microsatellite instability detection

The (Pathology) IT Crowd?
Digital and computational pathology
The (Pathology) IT Crowd?

December 30, 2021

5 min read

The pathologist’s guide to IT considerations for digitization

Defining the Next Generation of NGS
Digital and computational pathology
Defining the Next Generation of NGS

December 31, 2021

1 min read

Overcoming challenges of the typical NGS workflow with the Ion Torrent™ Genexus™ System

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.